Predictive models are an integral part of current clinical practice and help determine optimal treatment strategies for individual patients. A drawback is that covariates are assumed to have constant effects on overall survival (OS), when in fact, these effects may change during follow-up. Furthermore, breast cancer patients may experience events that alter their prognosis from that time onwards. We investigated the 'dynamic' effects of different covariates on OS and developed a nomogram to calculate 5-year dynamic OS (DOS) probability at different prediction timepoints (tP) during follow-up.
A B S T R A C T Background
Predictive models are an integral part of current clinical practice and help determine optimal treatment strategies for individual patients. A drawback is that covariates are assumed to have constant effects on overall survival (OS), when in fact, these effects may change during follow-up. Furthermore, breast cancer patients may experience events that alter their prognosis from that time onwards. We investigated the 'dynamic' effects of different covariates on OS and developed a nomogram to calculate 5-year dynamic OS (DOS) probability at different prediction timepoints (tP) during follow-up.
Methods
Dutch and Belgian postmenopausal, endocrine-sensitive, early breast cancer patients enrolled in the TEAM trial were included. We assessed time-varying effects of specific covariates and obtained 5-year DOS predictions using a proportional baselines landmark supermodel. Covariates included age, histological grade, hormone receptor and HER2 status, T-and N-stage, locoregional recurrence (LRR), distant recurrence, and treatment compliance. A nomogram was designed to calculate 5-year DOS based on individual characteristics.
Results
2602 patients were included (mean follow-up 6.2 years). N-stage, LRR, and HER2 status demonstrated time-varying effects on 5-year DOS. Hazard ratio (HR) functions for LRR, high-risk N-stage(N2/N3) and HER2 positivity were HR=(8.427•0.583tP), HR=(3.621•0.816tP) and HR=(1.235•0.851tP), respectively. Treatment discontinuation was associated with a higher mortality risk, but without a time-varying effect (HR 1.263 (95%CI 0.867-1.841)). All other covariates were time-constant.
Conclusion
The current nomogram accounts for elapsed time since starting adjuvant endocrine treatment and optimises prediction of individual 5-year DOS during follow-up. The nomogram can facilitate in determining whether further therapy will benefit an individual patient.
I N T R O D U C T I O N
Breast cancer comprises a heterogeneous disease with diverse features that can interact with outcomes, making it difficult to obtain estimations of individual prognoses. The overwhelming popularity of tools such as Adjuvant! or the Nottingham Prognostic Index (NPI) illustrates the importance of prediction models for physicians and patients, providing guidance for adjuvant treatment decisions. 1, 2 Most prediction models, however, cannot be used for cancer patients at specific timepoints during the follow-up period, as these models have been designed for use immediately after diagnosis. Apart from the caveats associated with available 'static' prediction models, there are some important reasons why these models may give misleading results when used during follow-up. First, the fact that patients have already survived a number of years after diagnosis may change a patient's prognosis. For instance, breast cancer recurrence rates peak at 1-2 years after diagnosis and decline thereafter, resulting in an improved prognosis. [3] [4] [5] Second, in the time between diagnosis and the moment of prediction, important events may have taken place, such as locoregional recurrence (LRR) and/or distant recurrences (DR) or premature discontinuation of treatment, which may alter a patient's prognosis. Third, some variables included in current models may exhibit timevarying effects on outcome, resulting in a change in mortality risk as time progresses. Consequently, too much emphasis may be placed on variables with a strong impact on outcome early in the follow-up period, whereas this effect might be much smaller later on.
Available static models are based on probabilities of survival at the time of diagnosis and may not accurately portray a patient's survival probability later on in the follow-up period. The concept of updating survival probabilities by both incorporating time-varying covariates and allowing for time-varying effects is called dynamic prediction. By design, these variables are not included in the static risk prediction models, and these considerations illustrate a need for better prediction models for cancer patients.
To investigate the clinical applicability of dynamic prediction, we utilized a dataset from a large randomized clinical trial of postmenopausal hormone receptor-positive early breast cancer patients treated with endocrine treatment (ET) in the Netherlands and Belgium. The aim of the current analysis was to develop a clinically applicable nomogram to facilitate the prediction of an individual patient's probability of surviving an additional 5 years at any prediction timepoint (tP) up to three years after starting adjuvant ET. This concept of continually updating 5-year overall survival (OS) from a certain tP is referred to as 5-year dynamic overall survival (DOS). We designed a dynamic predictive model, taking into account various patient-and tumor-specific covariates with time-varying and time-constant effects during follow up.
M A T E R I A L S A N D M E T H O D S
The Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial is a randomized, phase III, multinational, open-label study conducted in postmenopausal women with hormone receptor-positive breast cancer, who were eligible for adjuvant ET and randomized to either 5 years of exemestane (25mg) or 2.5-3 years of tamoxifen (20mg) followed by exemestane (25mg) for 2.5-2 years. 6 The TEAM trial protocol was approved by regulatory and ethics authorities of all participating centers in all participating countries. The trial was registered in the Netherlands and Belgium with the Netherlands Trial register, NTR 267. All patients provided written informed consent. Details of the study and data collection have been published previously. 6 In the Netherlands and Belgium, 3168 postmenopausal, early breast cancer patients were enrolled in the TEAM trial. Patients who did not start randomized treatment (n=19) or had missing endpoint data (n=4), metastatic disease before the start of ET (n=7), and patients with missing data regarding covariates used in the model (n=528) were excluded ( Figure 1 ). Patients with estrogen receptor (ER) and progesterone receptor (PR)-negative disease (n=8) were excluded.
The primary outcome of the present investigation was OS, which was the time from randomization to the date of death or last recorded follow-up. LRR was defined as any breast cancer recurrence in the ipsilateral breast and/or lymph nodes as well as in supraclavicular lymph nodes. DR comprised all other accounts of breast cancer recurrence.
Figure 1. CONSORT diagram of patients included in the analyses

Statistical analysis
Statistical analyses were performed using the programs SPSS (version 20) and R (version 2.15.1). We used the proportional baselines landmark supermodel 7, 8 to obtain dynamic predictions of the 5-year DOS probability. The model requires a number of landmark timepoints (t LM ); in the current model t LM was established at every third month between 0 and 3 years after the start of ET. A prediction model for 5-year DOS at a specific t LM is constructed by selecting the individuals at risk at that t LM and incorporating the values of any time-dependent covariates at that respective t LM in a Cox proportional hazards model. 9 The landmark prediction models at different t LM s may be combined into a single supermodel (Appendix 1). Using this analysis in the clinical setting, we can obtain DOS predictions at any prediction timepoint, tP, between 0 and 3 years after starting adjuvant ET. For this specific model, the prediction window was set to 5 years after the established tP .
Baseline patient-and tumor-specific factors included in the model comprised age at diagnosis (continuous, linear and quadratic terms), Bloom&Richardson (BR) histological grade (I,II,III), tumor stage (1,2,3/4), nodal stage (N0,N1,N2/N3), ER and PR status (positive,negative), HER2 status (positive,negative, missing), most extensive surgery (mastectomy,breast conserving surgery), radiotherapy (yes,no), chemotherapy (yes,no). ER and PR status were considered positive if at least 10% of tumor cells stained positively following immunohistochemical staining, as defined by the Dutch breast cancer treatment guidelines. 10 The model also included three dynamic variables whose values may change during ET, namely current ET status (on versus off ET), LRR (yes,no) and DR (yes,no). To assess whether a patient had stopped treatment, we used the last treatment date, as reported on the case-report forms. If no last treatment date was available, the patient was assumed to be on-treatment. According to the TEAM trial protocol, patients with LRR or DR discontinued or switched ET.
In order to test for time-varying covariate effects, interactions between covariates and t LM (both linear and quadratic) were included in the model. A backward selection procedure was then performed in two steps. In the first step all quadratic t LM interactions with the covariates were tested. Non-significant quadratic interactions were removed, and those covariates which did not have significant interactions in the first step were then tested in the second step for linear t LM interactions. Again, only significant interactions were retained. Wald-tests, based on robust standard errors, were used and a p-value of 0.05 was considered statistically significant (Appendix 1). Main effects of the covariates and of t LM and t LM 2 were included, irrespective of statistical significance. The model was then validated by internal calibration using the heuristic shrinkage factor by van Houwelingen et al. 11 The model's ability to correctly discriminate between patients was evaluated using the dynamic cross validated c-index. A c-index of 1 resembles a model that can perfectly discriminate between patients, while with a c-index of 0.5, the prediction is as good as chance. 7
Nomogram
The nomogram is a user-friendly tool for calculating survival probabilities based on a prediction model, and graphically computes 5-year DOS based on an individual patient's unique characteristics. For each prognostic factor, a number of risk points are assigned to each corresponding covariate, which can be read off the nomogram. The sum of the risk points represents a total risk point score, from which the corresponding 5-year DOS probability can be assessed at any tP (between 0 and 3 years) after the start of ET.
R E S U L T S
In total, 2602 TEAM trial patients with a median age of 64.8 years (range 38-92 years), were included in the analyses (Figure 1 ). Baseline characteristics of included patients are depicted in Table 1 . The majority of patients included in this trial had adjuvant radiotherapy (66%) and did not receive adjuvant chemotherapy (68%). Figure 2 provides an overview of the total number of patients in the landmark datasets at successive t LM s in relation to treatment compliance and disease recurrence status. Table 2 depicts the regression coefficients and hazard ratios (HR) with 95% confidence intervals (95% CI) of the covariates included in the model. Covariates with time-constant effects and covariates with time-varying effects on 5-year DOS are shown. Age at diagnosis demonstrated a time-constant effect, with 5-year DOS being a quadratic function of age (Appendix 2). Interestingly, high-risk nodal stage (N2/N3), compared to N0, demonstrated a significant time-varying effect on 5-year DOS with each successive tP, while nodal stage N1 did not ( Figure 3A) . To illustrate, the HR of a patient with nodal stage N2/N3 immediately after primary treatment compared to a patient with nodal stage N0 (reference) is 3.621, (calculated by the following formula: HR=[(constant) • (time-varying effect)tP]=3.621 • 0.8510)( Table 2) , but decreases to 2.411 (HR=3.621 • 0.8512 =2.411) at two years after the start of ET. HER2 positive status also demonstrated a significant time-varying effect on 5-year DOS (Table 2, Figure 3B ).
Next, covariates whose status have the potential to change over time (i.e. treatment compliance status and disease recurrence) were investigated for their influence on 5-year mortality risk. Patients who went off-treatment during the follow-up period had a higher residual mortality risk compared to patients who remained compliant, although this was not statistically significant. The effect of treatment discontinuation was constant over time (Table 2) . Simultaneously, LRR had a time-varying influence on 5-year DOS, revealing a subsiding mortality risk with each successive t LM ( Figure 3C ). Compared with no LRR, having a LRR at 1, 2, and 3 years after the start of ET increased 5-year mortality risk with HR=4.913 (2.444-9.877), HR=2.864 (1.851-4.431), and HR=1.670 (1.005-2.773), respectively (Table 2 ). In contrast, developing distant metastases (versus no distant metastases) was associated with an increased 5-year mortality risk, with a constant effect over time (HR=15.018 (9.934-22.705)). Figure 4 illustrates differences in the 5-year DOS in the event of a LRR in a patient who presents with the most commonly occurring baseline characteristics (average patient) found in this cohort, as well as in a high-risk patient. In the absence of a LRR, 5-year mortality probabilities are approximately 3% and 10%, respectively, at all tPs. However, in case of a LRR, 5-year mortality probabilities in both the average patient and the high-risk patient are initially high, and decrease with time.
Internal model validation
The heuristic shrinkage factor was 0.995, indicating good calibration of the model. Furthermore, the model's discriminatory accuracy had a dynamic cross validated c-index of 0.70, 0.72, 0.76 and 0.79 at 0, 1, 2 and 3 years respectively. tP , prediction timepoint; LRR, Locoregional Recurrence. Hazard ratios for nodal stage, HER2 status and locoregional recurrence status as time since the start of endocrine treatment (tP) increases (depicted as a hazard ratio with 95% confidence interval).
Figure 3. Time-varying hazard ratios for Nodal stage, HER2 status and Locoregional Recurrence status
Using the nomogram The nomogram ( Figure 5 ) provides estimates for 5-year DOS probabilities at different tPs from the start of ET and onwards, provided that adequate surgery has been performed. The probabilities can be calculated by adding the risk points for each covariate corresponding to the patient's individual characteristics. For each characteristic, the number of associated risk points can be determined by drawing a vertical line straight up from the covariate's corresponding value to the axis with risk points (0 to 80). While the majority of covariates are considered 'static' and defined at the start of ET, some covariates are 'dynamic', such as treatment compliance status and the occurrence of LRR or distant metastases during follow-up. In addition, three covariates (nodal stage (N2/N3), HER2 status (positive) and LRR) demonstrated time-varying effects on 5-year DOS. Hence, 5-year DOS for these specific covariates depends on the tP, and for these specific covariates each subgroup has an individual time-interaction axis. The sum of the risk points is equal to the total risk point score, which is depicted on the axis of the nomogram entitled "Total Points". From here, a vertical line can be drawn towards the axis labelled "5 Year Survival Probability", which is the corresponding 5-year DOS at that specific tP. To illustrate, we consider a 69-year-old postmenopausal woman (14 points) who has been using ET for two years (tP=2, 5 points). She had a grade III tumor (13 points) with a diameter of 1.5cm (0 points), ER-positive (0 points), PR-positive (0 points) and HER2-negative (0 points), and 5 tumor-positive lymph nodes (at tP=2, 55 points). The patient has undergone breast conserving surgery (2 points) with adjuvant radiotherapy (0 points) and adjuvant chemotherapy (0 points). She is still on-treatment (0 points) and disease-free (0 points) (no locoregional or DR). To calculate her 5-year DOS probability, we take her total risk point score (89 points) and draw a vertical line down to the '5-year survival probability' axis. For this patient, the 5-year DOS is 94%. If our patient had developed a LRR in the 2-year period since ET, one must add an additional 40 points (total=129 points) to her total risk prediction score, resulting in a 5-year DOS of 84%.
D I S C U S S I O N
To our knowledge this is the first dynamic prediction model in clinical oncology, designed to optimise the prediction of the 5-year DOS at specific timepoints after the start of adjuvant ET. The key advantage of this model is that it takes into account dynamic factors that can influence a patient's prognosis after some time has passed since starting ET, including treatment compliance and the occurrence of LRR or distant metastases. Moreover, covariates with time-varying effects are also accounted for in the model, including high-risk nodal stage (N2/N3) and HER2 positive status.
Current nomograms are suboptimal for cancer patients, because their reference point is commonly the time of diagnosis or the start of adjuvant ET. Aiming at further personalized breast cancer treatment, continuous re-evaluation of the residual risk of breast cancer recurrence and mortality during follow-up is crucial. Patients may develop disease recurrences or discontinue ET before the pre-designated end-date, which may alter a patient's prognosis from that timepoint onwards. Additionally, the effect of a covariate on 5-year survival probabilities may not be constant over time. These changes are more prominent than current statistical models account for, which could lead to the risk of developing less effective treatment guidelines. Therefore, survival prediction models need to be adapted for long-term outcome prediction in individual patients. Specifically, dynamic prediction models can be used to determine whether a patient will benefit from further adjuvant systemic therapy or, conversely, whether ET can be discontinued at a certain timepoint during follow-up. The current nomogram can be applied to postmenopausal, hormone receptor-positive breast cancer patients undergoing adjuvant ET and have had an axillary lymph node dissection in case of macrometastases. For patients who have had breast-conserving surgery, the model assumes that the breast was irradiated. The current nomogram also assumes that disease relapse implies discontinuation of ET from that moment onwards. In case of disease recurrence, data on subsequent treatment were not available for all patients, hence our ability to draw conclusions for this subgroup is limited.
LRR is considered a 'dynamic' covariate, as patients can develop a LRR at any moment during follow-up. LRR also had 'time-varying' properties, as the event of a LRR revealed a changing impact on 5-year DOS at different timepoints after starting ET. Our findings parallel those of several other studies, which have shown that early LRRs convey a worse prognosis than late LRRs. [12] [13] [14] [15] [16] It can therefore be of major clinical importance to include this factor in dynamic survival prediction. Moreover, this model could potentially help evaluate the need for additional adjuvant chemotherapy in case of LRR. Data on the benefit of additional chemotherapy are still relatively lacking, although the nomogram could be useful in this setting. The current model also revealed a time-varying relationship between high nodal stage (N2/3) and 5-year DOS probability. A similar time-varying effect was shown with regard to 5-year DOS in HER2-positive patients, although no patients received anti-HER2 treatment. To our knowledge, no prior reports have investigated the time-varying effects of these two prognostic factors, hence warranting further investigation. Our dynamic prediction model also accounts for the effect of early treatment discontinuation for reasons other than breast cancer relapse. Although the effect of treatment discontinuation did not reach statistical significance, possibly due to the low number of patients who discontinued treatment within three years (Figure 2 , left panel), we retained this data in our model, as an earlier review revealed the importance of treatment compliance on survival outcomes. 17 The number and site(s) of DR are known to be prognostic for subsequent survival. [18] [19] [20] The dynamic prediction model incorporates the occurrence of distant metastases, but does not include this in the nomogram due to insufficient data concerning first site of DR and subsequent treatment. For this reason, it is not advised to use the dynamic prediction model for patients with distant metastases as first site of disease recurrence.
Internal validation demonstrated that the model had a good ability to discriminate between patients. To elucidate, internal validation of Adjuvant! showed a c-index of 0.71 for discriminatory accuracy (the ability for the model to distinguish patients who will versus those who will not die from breast cancer) and a predictive accuracy of 0.73 at diagnosis, which is similar to that of our prediction model. 21 The predictive accuracy of Adjuvant! after diagnosis has not been studied; in contrast, our dynamic prediction model showed a cross-validated c-index that improved from 0.70 to 0.79 three years after the start of adjuvant ET. Further external validation of the prediction model is required in greater (non-trial) cohorts to allow for full applicability in the clinical setting. A web-based dynamic prediction tool is currently underway to facilitate decision making in clinical practice.
C O N C L U S I O N
The importance of using dynamic prediction models for clinical guidance, not only at the start of treatment, but also during follow-up, permits continuous revision of a patient's residual mortality risk and can help motivate a patient to continue treatment, improve compliance, and ultimately improve survival. This proof-of-principle study demonstrates a novel technique for performing dynamic prediction of breast cancer survival probabilities over time, enabling a more individualized prediction of the 5-year DOS in individual patients at various timepoints during adjuvant ET. The most important advantage of this model is that it takes into account factors that can influence an individual patient's prognosis after some time has passed since starting adjuvant ET. Notwithstanding the feasibility of our dynamic prediction model, further external validation with longer follow-up is necessary to enable implementation in clinical practice. 
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